SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021
March 03, 2022 16:05 ET
|
SIGA Technologies Inc.
- Approximately $113 Million of U.S. Product Sales in 2021 – - Approximately $13 Million of International Product Sales in 2021 – - Corporate Update Conference Call Today at 4:30...
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
March 02, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 10:27 ET
|
SIGA Technologies Inc.
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
January 25, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
January 18, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it...
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
January 10, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®
December 01, 2021 09:55 ET
|
SIGA Technologies Inc.
NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that...
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat
November 16, 2021 08:30 ET
|
SIGA Technologies Inc.
- Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications - NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a...
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
November 04, 2021 16:05 ET
|
SIGA Technologies Inc.
- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - - Approximately $13 Million of International Sales for the First Nine Months of...
SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
October 28, 2021 16:15 ET
|
SIGA Technologies Inc.
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...